Literature DB >> 1977781

A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects.

F E Simons1, J L McMillan, K J Simons.   

Abstract

We objectively tested the relative antihistaminic effects of cetirizine, 10 mg; terfenadine, 120 mg; terfenadine, 60 mg; loratadine, 10 mg; astemizole, 10 mg; chlorpheniramine, 4 mg; and placebo in healthy, male volunteers, mean age 25 +/- 4 years, and mean weight, 73 +/- 9 kg. The wheal areas and flare areas produced by epicutaneous tests with histamine phosphate, 1 mg/ml, before ingestion of the H1-receptor antagonist or placebo, and afterward, at 0.3 and 0.7 hours, then hourly from 1 to 12 hours and at 24 hours, were traced at 10 minutes and measured with an IBM-PC digitizer and stereometric software. In this experimental model, the H1-receptor antagonists differed significantly with regard to time of onset of action, amount of suppression of the histamine-induced wheal and flare, and duration of action. The rank order was, from most effective to least effective, cetirizine, 10 mg; terfenadine, 120 mg; terfenadine, 60 mg; loratadine, 10 mg; astemizole, 10 mg; chlorpheniramine, 4 mg; and placebo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977781

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  33 in total

1.  Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h.

Authors:  A Purohit; M Mélac; G Pauli; N Frossard
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

4.  Design of a suitable formulation of FK613, a novel antiallergic agent, based on its pharmacokinetic and pharmacodynamic properties in healthy subjects.

Authors:  T Uematsu; S Nagashima; H Inaba; T Kajiho; H Kageyama; A Sugiyama; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

5.  Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy.

Authors:  Melanie C Dispenza; Jacqueline A Pongracic; Anne M Singh; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2018-01-31       Impact factor: 10.793

Review 6.  Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 7.  Effects of antihistamine medications on exercise performance. Implications for sportspeople.

Authors:  L C Montgomery; P A Deuster
Journal:  Sports Med       Date:  1993-03       Impact factor: 11.136

8.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Contact urticaria: present scenario.

Authors:  Ruchi Bhatia; Ali Alikhan; Howard I Maibach
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

10.  Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.

Authors:  Nerea Jauregizar; Leire de la Fuente; Maria Luisa Lucero; Ander Sologuren; Nerea Leal; Mónica Rodríguez
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.